BridgeBio Pharma, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2023-11-02: Disclosure Material Terms Of Trading Arrangement; Period 2023-01-01..2023-09-30; Value On August 16, 2023 , Hannah A. Valantine , a member of our Board of Directors , adopted a trading plan for the sale of a maximum of 34,980 shares of our common stock (the “Trading Plan”). The Trading Plan is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-….
- 2023-08-03: Disclosure Material Terms Of Trading Arrangement; Period 2023-01-01..2023-06-30; Value On June 6, 2023 , Randal W. Scott, Ph.D . , a member of our Board of Directors , adopted a trading plan for the sale of a maximum of 16,000 shares of our common stock (the “June 6 Plan”). The June 6 Plan is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1….
- 2023-04-28: Disclosure Pay versus Performance Table; Period 2022-01-01..2022-12-31; Value Pay-Versus-Performance Table Year Summary Compensation Table Total for PEO 1 Compensation Actually Paid to PEO 2 Average Summary Compensation Table Total for Non-PEO Named Executive Officers 3 Average Compensation Actually Paid to Non-PEO Named Executive Officers 4 Value of Initial Fixed $100 Invest….
- 2023-04-28: Disclosure Adjustment To PEO Compensation Footnote; Period 2022-01-01..2022-12-31; Value 2 The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Kumar, as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid….
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2023-11-02 10-Q | Material Terms Of Trading Arrangement | 2023-01-01..2023-09-30 | On August 16, 2023 , Hannah A. Valantine , a member of our Board of Directors , adopted a trading plan for the sale of a maximum of 34,980 shares of our common stock (the “Trading Plan”). The Trading Plan is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-… | |
| 2023-08-03 10-Q | Material Terms Of Trading Arrangement | 2023-01-01..2023-06-30 | On June 6, 2023 , Randal W. Scott, Ph.D . , a member of our Board of Directors , adopted a trading plan for the sale of a maximum of 16,000 shares of our common stock (the “June 6 Plan”). The June 6 Plan is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1… | |
| 2023-04-28 DEF 14A | Pay versus Performance Table | 2022-01-01..2022-12-31 | Pay-Versus-Performance Table Year Summary Compensation Table Total for PEO 1 Compensation Actually Paid to PEO 2 Average Summary Compensation Table Total for Non-PEO Named Executive Officers 3 Average Compensation Actually Paid to Non-PEO Named Executive Officers 4 Value of Initial Fixed $100 Invest… | |
| 2023-04-28 DEF 14A | Adjustment To PEO Compensation Footnote | 2022-01-01..2022-12-31 | 2 The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Kumar, as computed in accordance with Item 402(v) of Regulation S-K, for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or paid… | |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: GrantDateFairValueOfEquityAwards; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $4.57M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustment; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$13.45M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: GrantDateFairValueOfEquityAwards; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $24.87M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustment; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$133.51M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: GrantDateFairValueOfEquityAwards; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $8.67M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustment; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $149.67M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfAllOutstandingAndUnvestedEquityAwardsGrantedDuringCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $2.33M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$9.05M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInSameCoveredFiscalYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $1.68M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | -$8.41M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: Peo | 2022-01-01..2022-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfAllOutstandingAndUnvestedEquityAwardsGrantedDuringCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $4.39M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$115.12M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInSameCoveredFiscalYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $1.23M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | -$24.02M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: Peo | 2021-01-01..2021-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfAllOutstandingAndUnvestedEquityAwardsGrantedDuringCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $29.02M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $117.77M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInSameCoveredFiscalYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $1.48M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $1.40M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: Peo | 2020-01-01..2020-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Named Executive Officers Footnote | 2022-01-01..2022-12-31 | 3 The dollar amounts reported in column (d) represent the average of the amounts of total compensation reported for our NEOs as a group (excluding Dr. Kumar, who has served as our PEO since BridgeBio’s founding in April 2015) for each covered fiscal year in the “Total” column of the Summary Compensa… | |
| 2023-04-28 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2022-01-01..2022-12-31 | 4 The dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to our NEOs as a group (excluding Dr. Kumar), as computed in accordance with Item 402(v) of Regulation S-K for each covered fiscal year. The dollar amounts do not reflect the actual average amoun… | |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: GrantDateFairValueOfEquityAwards; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $1.81M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustment; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$1.93M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: GrantDateFairValueOfEquityAwards; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $7.84M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustment; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$23.95M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: GrantDateFairValueOfEquityAwards; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $3.58M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustment; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $17.26M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfAllOutstandingAndUnvestedEquityAwardsGrantedDuringCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $921.75K |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$2.07M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInSameCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $664.33K |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | -$1.45M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2022-01-01..2022-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfAllOutstandingAndUnvestedEquityAwardsGrantedDuringCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $1.48M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$21.88M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInSameCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $400.74K |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | -$3.96M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2021-01-01..2021-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfAllOutstandingAndUnvestedEquityAwardsGrantedDuringCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $6.19M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $9.67M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInSameCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $2.59M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $313.29K |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfAnyOutstandingAndUnvestedEquityAwardsGrantedInAnyPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $1.51M |
| 2023-04-28 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2020-01-01..2020-12-31 | $0.00 |
| 2023-04-28 DEF 14A | Peer Group Issuers Footnote | 2022-01-01..2022-12-31 | 6 Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the following published industry index: Nasdaq Biotechnology Index. | |
| 2023-04-28 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2022-01-01..2022-12-31 | Compensation Actually Paid and Company TSR As demonstrated by the following graph, the amount of compensation actually paid to our CEO and the average amount of compensation actually paid to our other NEOs as a group (except Dr. Kumar) is generally aligned with our TSR over the period presented in t… | |
| 2023-04-28 DEF 14A | Total Shareholder Return Vs Peer Group | 2022-01-01..2022-12-31 | Compensation Actually Paid and Company TSR As demonstrated by the following graph, the amount of compensation actually paid to our CEO and the average amount of compensation actually paid to our other NEOs as a group (except Dr. Kumar) is generally aligned with our TSR over the period presented in t… | |
| 2023-04-28 DEF 14A | Compensation Actually Paid Vs Net Income | 2022-01-01..2022-12-31 | Compensation Actually Paid and Net Loss Attributable to Common Stockholders of BridgeBio As demonstrated by the following graph, the amount of compensation actually paid to our CEO and the average amount of compensation actually paid to our other NEOs as a group (except Dr. Kumar) increased in 2022 … | |
| 2023-04-28 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2022-01-01..2022-12-31 | Compensation Actually Paid and Revenue As demonstrated by the following graph, the amount of compensation actually paid to Dr. Kumar and the average amount of compensation actually paid to our other NEOs as a group (except Dr. Kumar) is generally aligned with our revenue over the period presented in… |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |